Exchange: NASDAQ·Updated 07:22 PM EDT
UTHR logo

UTHRUnited Therapeutics Corp

$541.00
$5.13
(0.97%)
Today
Closed $531.79
$9.21
(1.73%)
After Hours
EarningsJul 29
Mkt Cap$22.35B
Vol448,059.00
News
all
press releases
Can LQDA's Yutrepia Drive Growth in the Competitive PAH Market?
LQDA's Yutrepia posts a strong commercial debut, but sustaining growth will hinge on standing out in the crowded PAH market as competition intensifies.
Zacks
News Placeholder
More News
News Placeholder
BETA Technologies and Multistate Collaborative Complete First Operational Flights of the U.S. DOT and FAA's eVTOL Integration Pilot Program
BETA Technologies, Inc. (BETA) (NYSE: BETA), an aerospace and defense company, and the Multistate Collaborative eIPP National Integration Complex today announced the completion of the first electric conventional takeoff and landing (CTOL) aircraft flights conducted under the U.S. Department of...
Business Wire
News Placeholder
United Therapeutics Stock Rises 14% YTD: Here's What You Need to Know
UTHR's strong clinical wins for Tyvaso and ralinepag, along with progress in organ manufacturing, are boosting growth prospects despite rising PAH competition.
Zacks
News Placeholder
Want Better Returns? Don't Ignore These 2 Medical Stocks Set to Beat Earnings
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
Zacks
News Placeholder
LQDA Stock Soars 129.7% YTD: Is There More Room for Growth?
Liquidia has surged 129.7% so far in 2026 as Yutrepia gains traction, driving strong sales, profitability and higher earnings estimates.
Zacks
News Placeholder
UTHR Strengthens Regenerative Medicine Platform With Thymmune Deal
United Therapeutics acquires Thymmune, adding preclinical thymic cell therapy THY-100 & expanding its regenerative medicine pipeline for organ transplantation.
Zacks
News Placeholder
Can Yutrepia Maintain Momentum for LQDA Stock in 2026?
LQDA's Yutrepia launch is gaining traction, with $130 million in Q1 sales, rising prescriptions and profitability as the company expands in PAH.
Zacks
News Placeholder
United Therapeutics Buys Thymmune Therapeutics
(RTTNews) - United Therapeutics Corp. (UTHR) on Thursday announced the acquisition of privately held Thymmune Therapeutics for up to $300 million...
Nasdaq News: Markets
News Placeholder
United Therapeutics Acquires Thymmune Therapeutics For $140M In Cash, Plus Up To $160M In Milestone-Based Earn-Outs Through 2031
United Therapeutics Corporation (Nasdaq: UTHR) announced today it has acquired Thymmune Therapeutics, Inc. (Thymmune), a privately held, preclinical stage biotechnology company developing scalable, regenerative thymicread more...
Benzinga
News Placeholder
United Therapeutics Corporation Acquires Thymmune Therapeutics
United Therapeutics Corporation (Nasdaq: UTHR) announced today it has acquired Thymmune Therapeutics, Inc. (Thymmune), a privately held, preclinical stage biotechnology company developing scalable, regenerative thymic cell therapies for the potential treatment of post-transplant organ tolerance...
Business Wire
<
1
2
...
>

Advertisement|Remove ads.